An inflammatory trigger like one present during viral infections is elevated in those with Alzheimer's disease and progressive supranuclear palsy (PSP).
People who later developed Alzheimer's disease scored poorly on memory and logic-based tests, as well as reaction times and grip tests. They were also more likely to have experienced a fall within the past 12 months. Those who developed PSP were twice as likely to experience a fall.
Researchers have identified multiple new risk genes for Alzheimer's disease and progressive supranuclear palsy (PSP).
A new deep learning algorithm utilizes neuroimaging data to differentiate between Parkinson's disease and other parkinsonian syndromes such as PSP and multiple systems atrophy.
Study confirms neurofilament light is a useful blood-based biomarker for frontotemporal dementia, PSP, and primary progressive aphasia.
Patients who suffer from frontotemporal dementia with extrapyramidal symptoms have brainstem atrophy and reduced metabolic activity in specific brain regions compared to those with FTD without extrapyramidal symptoms.
Degeneration of neurons associated with wakefulness, and not a lack of sleep, makes Alzheimer's patients more drowsy. The degeneration of these neurons is caused by the tau protein. In PSP, the damage to the neurons was associated with symptoms of sleep deprivation.
Alpha2-NKA, a protein that drives toxicity in astrocytes, was discovered in higher levels of brain samples from people who died of PSP, Alzheimer's and other tau-related neurodegenerative disorders. Treatment with an FDA-approved drug called digoxin may suppress the inflamed astrocytes and halt disease progression for those with tauopathy disorders.
Researchers have identified a layer of genetic material involved in controlling the production of tau in the brain. The material is part of a larger family of non-coding genes that regulate and control other brain proteins associated with neurodegenerative disorders, such as Alzheimer's disease, Parkinson's, and PSP. The findings could lead to the development of new therapeutics to treat a range of neurodegenerative disorders.
Progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS), two atypical parkinsonian syndromes, may be twice as common as previously believed, researchers report.
Tau accumulations disrupt wake-promoting neurons. The findings help explain why day-time napping and sleep disruptions are often reported in Alzheimer's patients.
VPS35 is a novel critical component of tau metabolism and the pathology of neurodegenerative diseases.
